Atea Pharmaceuticals

Biotech & Life Sciences · Boston, United States · Founded 2014 · IPO 2020

Innovative oral antiviral therapies transforming treatments for serious viral diseases MoreLess

Atea Pharmaceuticals is a pioneering company in the discovery, development, and commercialization of oral direct-acting antiviral therapies. The company's most advanced drug candidate, bemnifosbuvir, is designed to treat severe viral infections, including Hepatitis C and COVID-19. Atea operates in the pharmaceutical market, focusing on patients affected by serious viral diseases. The business model revolves around developing innovative antiviral drugs and forming strategic collaborations, such as the partnership with Roche to develop and commercialize AT-527 for COVID-19 patients. Revenue is generated through the commercialization of these therapies and strategic partnerships. Atea serves healthcare providers and patients worldwide, aiming to transform the treatment landscape for viral infections.

Keywords: antiviral, oral therapies, Hepatitis C, COVID-19, bemnifosbuvir, Roche collaboration, pharmaceutical, healthcare, innovation, viral diseases.

Valuation $100–500M

Headcount <100

Total funding $100–500M

Power Law Thoroughbred$100M+ revenue

Talent graph

Atea Pharmaceuticals's talent

Book a demo to see the people

Employees mapped 58 incl. 1 AI specialist

Founders /100 quality score

Key operators 29 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

4 investors on Atea Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

RMI Partners

Series B+ 3 investors entered at this stage

Bain Capital Life Sciences

Omega Funds

Perceptive Advisors

Global footprint

Where Atea Pharmaceuticals has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States97.8%

🇧🇷 Brazil2.2%

2 countries shown

Web traffic by country

2.9K monthly visits
across markets

🇺🇸 United States82.8%

🇮🇳 India17.2%

Top 2 markets shown

Patent intelligence

$46M patent portfolio · 25 active families

Estimated portfolio value

$46M

38.4% of market cap · 8.9× smaller than top peer Supernus Pharmaceuticals ($413M)

25 active patent families

Where Atea Pharmaceuticals innovates DiseaseHepatitis viral cMedicinal chemistryMolecular biologyNucleotide

Where Atea Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Atea Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Atea Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Atea Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Atea Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles